<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Inherited and acquired tendency to the formation of clots represents an important cause of morbidity and mortality for ischemic events in young people (aged between 40 and 50 years) that is more and more frequently identified </plain></SENT>
<SENT sid="1" pm="."><plain>The haemostasis' disorders may happen on the venous or arterial side </plain></SENT>
<SENT sid="2" pm="."><plain>Arterial <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> is a 'white' <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e>, also called temporary <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>It consists of aggregate platelets only </plain></SENT>
<SENT sid="4" pm="."><plain>On the contrary, venous <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> is 'red' or permanent <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> composed of platelets, red cells and fibrin </plain></SENT>
<SENT sid="5" pm="."><plain>The first is the result of platelets' <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> or aggregation </plain></SENT>
<SENT sid="6" pm="."><plain>Instead, the permanent <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> derives from the coagulant factors successively acting on 'white' <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>The different pathogenesis justifies both the distinction between '<z:hpo ids='HP_0100724'>hypercoagulability</z:hpo>' and '<z:hpo ids='HP_0100724'>thrombophilia</z:hpo>' and the different treatments employed </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0003613'>Antiphospholipid antibody</z:hpo> syndrome, <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera, <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo>-acquired <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">hyperhomocysteinemia</z:e>, <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> and <z:mpath ids='MPATH_512'>myeloproliferative disease</z:mpath> are the most frequent causes of acquired <z:e sem="disease" ids="C0398623" disease_type="Disease or Syndrome" abbrv="">hypercoagulable state</z:e>, prevalently responsible for <z:hpo ids='HP_0002625'>deep venous thrombosis</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Among the inherited forms, congenital <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">hyperhomocysteinemia</z:e>, <z:e sem="disease" ids="C0584960" disease_type="Disease or Syndrome" abbrv="">factor V Leiden mutation</z:e>, proteins C and S deficiency and antithrombin mutation are included </plain></SENT>
<SENT sid="10" pm="."><plain>These may induce both venous and arterial <z:hpo ids='HP_0011009'>acute</z:hpo> events </plain></SENT>
<SENT sid="11" pm="."><plain><z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">Hyperhomocysteinemia</z:e> can be congenital and acquired and is more correctly named as '<z:hpo ids='HP_0100724'>thrombophilia</z:hpo>' rather than '<z:hpo ids='HP_0100724'>hypercoagulability</z:hpo>' </plain></SENT>
<SENT sid="12" pm="."><plain>That happens because it involves the platelets' aggregation rather than the coagulant cascade </plain></SENT>
<SENT sid="13" pm="."><plain>The optimal treatment of <z:hpo ids='HP_0100724'>thrombophilias</z:hpo> consists of oral (<z:chebi fb="8" ids="10033">warfarin</z:chebi>) or injectable (<z:chebi fb="0" ids="24505">heparins</z:chebi>) <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> </plain></SENT>
<SENT sid="14" pm="."><plain>Direct thrombin inhibitors, platelet <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> IIb/IIIa <z:chebi fb="68" ids="48706">antagonists</z:chebi>, and tissue factor inhibitors also appear to be some attractive approaches </plain></SENT>
<SENT sid="15" pm="."><plain>For acquired forms, treatments of their aetiologies must also be carried out </plain></SENT>
<SENT sid="16" pm="."><plain>For acquired <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">hyperhomocysteinemia</z:e>, both antiplatelets' therapy (aspirin + <z:chebi fb="0" ids="37941">clopidogrel</z:chebi>) and new direct thrombin inhibitors (as dabigatran) could be considered </plain></SENT>
<SENT sid="17" pm="."><plain>Finally, as secondary prevention of an arterial <z:hpo ids='HP_0011009'>acute</z:hpo> event (<z:hpo ids='HP_0001297'>stroke</z:hpo>, IMA or peripheral <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>) due to <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">hyperhomocysteinemia</z:e>, lifetime dual antiplatelets' therapy should be used </plain></SENT>
</text></document>